Finding the market’s top growth prospects at any given time is not too difficult. But finding stocks that can depreciate over the next five years is a different story. Their parent company needs to do everything right and do business in an industry that is poised for some serious sustained growth. A temporary fall in these stocks will also help. It’s a tall order to be sure.
But currently few such names are available for you. Here’s a deeper dive into three of the best stocks that have the potential to turn a $1,000 investment into a $5,000 position by the end of 2030.
Amazon(NASDAQ: AMZN ) Indeed, it is the leader of the Western Hemisphere. E-commerce State. According to Digital Commerce 360 numbers, it controls 40% of the North American market. It’s not doing terribly overseas either. Its global arm posted top-line growth of 12 percent in the third quarter of last year, pushing it deeper into the black and looking set to last. (The North American e-commerce arm has been profitable for some time, but is growing its operating income at an above-average clip.)
None of this is reason to consider getting into Amazon stock, pending a heroic five-year run from the stock.
Rather, the bullish argument here is the company’s core breadcrumb cloud computing business. You know it as Amazon Web Services or AWS. As a result of the 19% growth compared to the previous quarter’s revenue growth rate, AWS now accounts for more than 60% of the company’s operating income. That figure is still growing rapidly.
Data source: Amazon Inc. Chart by author. Figures are in the billions.
Cloud computing is only important because the market is expecting a lot of growth runway. Mordor Intelligence expects the global cloud computing market to grow at an average rate of more than 16 percent through 2030.
The continued expansion of Amazon’s e-commerce operations will not affect bullish writing. They look like investors Simplify it all.
The last four years have been tough. Iovance Biotherapeutics(NASDAQ: IOWA) shareholders. This stock was on a rampage between 2019 and 2020 before finally peaking at $54.21 in January 2021 and then dropping to a 2023 low of $3.21. The current price of about $6.00 isn’t much better.
However, this overhyped sell-off can sometimes be a fantastic buying opportunity based on the perception that investors are having a collective terrible time.
But first things first.
As the name suggests, Iovance Biotherapeutics is a biopharma brand. Its main product is a tumor-infiltrating lymphocyte (TL) treatment called lifileucel, but it has been in the works for years, and only received its first FDA approval (as a treatment for melanoma) in February 2024. While this was widely expected, it was still a huge achievement for a pre-revenue company.
The response was good. Evans sold nearly $60 million of the young (and expensive) drug in the three months ending in September 2024.
However, investors did not react to this success with any bullishness.
What does it give?
The move here is somewhat typical of small biopharma stocks working on a game-changing drug candidate. This company In 2019 and 2020, it burned with all its energy, driven by euphoria, when it became clear that Liflucel could be approved. In the three years between then and the approval, investors lost interest significantly.
It’s surprising that the story of the growth of Iowans biotherapeutics has never been more compelling than it is now. According to Credence research, the nascent tumor-infiltrating lymphocyte drug market is poised to grow at an annual clip of nearly 40%, potentially worth $2.5 billion. As Iovance is one of the first and few outfits to successfully work on this science, investors should start looking and valuing the future with its knowledge – and real growth.
Last but not least, add year(NASDAQ: ROKU ) In your list of stocks that could turn $1,000 into $5,000 by 2030.
Like Iovance, Roku’s shares soared in the early days of (and even because of) the Covid-19 pandemic. Millions of people are suddenly stuck at home with nothing to do but watch television. Roku streamers helped make it possible.
As expected following this unchecked meteoric rise in stocks, the market eventually began to realize that the high expectations at the time were meaningless. Shares in They lost more than 80% of their value between 2021 and 2022, where they have been stuck ever since. The company’s lack of profitability this time around didn’t help either.
Now take a closer look… well, look at everything Roku has and does. Despite giving up some share of late, Roku still controls 37 percent of the North American connected television (CTV) device market, according to industry research firm Pixalate. The next closest competitor in this crowded field is still only 17 percent behind.
The company isn’t doing well overseas, but is focusing a lot of time and resources on the domestic market, where it’s doing well and where most of the opportunity awaits. According to Global Markets Insights, the global streaming/video-on-demand market, led by North America, where more than 40% of this business is generated, will grow at an average rate of 11% through 2032.
That’s not all that’s poised to push this stock higher.
Although Roku will return to the red in 2021 after briefly swinging into profit during the outbreak, its current revenue and earnings trajectory puts it on track to return to the black again next year. It’s not likely to be a huge profit — analysts are looking for 2026 earnings of just $0.36 per share. But it is not appropriate to be the end of this development trend. The top and bottom line should continue to improve beyond that.
Data source: StockAnalysis. Chart by author.
Before this viability function is reached, the stock may well begin to rally, anticipating an increasingly obvious trend.
Before you buy stock in Amazon, consider this:
of Motley Fool Stock Advisor A panel of analysts identified what they believed. 10 best stocks For investors to buy now… and Amazon was not one of them. 10 stocks that made the cut could make monster returns in the coming years.
Think about when Nivea Created this list on Apr 15, 2005… If you invest $1,000 during our recommendation, You will have $843,960!*
Stock consultant It provides investors with an easy-to-follow blueprint for success, including guidance on portfolio construction, regular analyst updates, and two new stock picks every month. ofStock consultantIt has a service. More than four times Return of the S&P 500 since 2002*.
John McKee, former CEO of Whole Foods Market, a subsidiary of Amazon, is a member of the Motley Fool’s board of directors. James Brumley It has no place in the said shares. He has a spot in the Motley Fool and recommends Amazon, Iovance Biotherapeutics and Roku. The Motley Fool has Disclosure Policy.
